Product

Company

Clareo Health | Prediction of True Oligo-metastatic Disease.

NCT05806151·1 site·ClinicalTrials.gov

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Alessandro Ottaiano
CONTACT
+39 081 17770344 a.ottaiano@istitutotumori.na.it
Mariachiara Santorsola
CONTACT
+39 081 17770344 mariachiara.santorsola@istitutotumori.na.it

Lead

National Cancer Institute, Naples

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

Patients eligible for inclusion in this study must meet the following criteria:
Diagnosis of gastroenteric tumors (colon, stomach, biliary tract, exocrine glands of the digestive tract);
OMD: one to three lesions per organ with a maximum tumor diameter of less than 70 mm and no lesion with a diameter greater than 25 mm;
Availability of FFPE (Formalin Fixed Paraffin Embedded) inclusions from resected primary tumor;
Written informed consent.

The record

StatusUnknown

PhaseNo phase

Taking part32

StartedJan 2023

UpdatedApr 10, 2023

Conditions

Where1